Press Releases

November 7, 2018 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

SAN DIEGO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today reported

PDF Version
November 5, 2018 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility

SAN DIEGO , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, will officially cut the ribbon on its San Diego based research and development facility on Monday, with President and CEO Joseph Payne , San Diego Mayor Kevin L.

PDF Version
October 1, 2018 at 7:09 AM EDT

Summary Toggle Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

SAN DIEGO , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today reported

PDF Version
September 25, 2018 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at October Investor Conferences

SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph Payne will present at four investor conferences in October: Microcap Conference , Ladenburg Thalmann 4 th Annual Healthcare Conference, LEERINK

PDF Version
September 21, 2018 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Expands Management Team

Arcturus Appoints Senior VP of Business Development & Alliance Management and VP of Translational Biology SAN DIEGO , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced the appointment of Kevin T.

PDF Version
August 29, 2018 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor

SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ: ARCT), a leading RNA medicines company, today announced that at the Company’s Annual General Meeting of Shareholders on August 24, 2018 , shareholders of the Company approved the

PDF Version
August 28, 2018 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer

SAN DIEGO , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that it has appointed Andrew Sassine as Interim Chief Financial Officer (CFO), effective August 24, 2018 . Mr. Sassine has served on Arcturus’ Board of Directors

PDF Version
August 27, 2018 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Three Investor Conferences in September

SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph E. Payne will present at the upcoming conferences, including the B. Riley FBR Annual Healthcare Conference, the H.C. Wainwright & Co.

PDF Version
July 23, 2018 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis Foundation ( CF Foundation ) Therapeutics, Inc.

PDF Version
July 20, 2018 at 5:23 PM EDT

Summary Toggle Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

SAN DIEGO , July 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“ Arcturus ” or the “ Company ”) (NASDAQ:ARCT), an RNA medicines company, today announced that it will hold an Annual and Extraordinary General Meeting of Shareholders (or the “ Meeting ” ), on Friday, August 24, 2018 , at

PDF Version